Antidepressant drug prescription and incidence of COVID-19 in mental health outpatients: a retrospective cohort study | BMC Medicine
Haug N, Geyrhofer L, Londei A, Dervic E, Desvars-Larrive A, Loreto V, et al. Ranking the effectiveness of worldwide COVID-19 government interventions. Nat Hum Behav. 2020;4(12):1303–12.
Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A, et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021;184(16):4220-4236.e13.
Parker EPK, Desai S, Marti M, Nohynek H, Kaslow DC, Kochhar S, et al. Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review. Lancet Glob Health. 2022;10(3):e326–8.
Global Dashboard for Vaccine Equity [Internet]. UNDP Data Futures Platform. [Cited 5 Apr 2023]. Available from: https://data.undp.org/vaccine-equity/.
Venkatesan P. Repurposing drugs for treatment of COVID-19. Lancet Respir Med. 2021;9(7):e63.
Glebov OO. Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing. FEBS J. 2020;287(17):3664–71.
Harrison C. Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020;38(4):379–81.
Zhou Y, Wang F, Tang J, Nussinov R, Cheng F. Artificial intelligence in COVID-19 drug repurposing. Lancet Digit Health. 2020;0(0). https://doi.org/10.1016/S2589-7500.
Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19. N Engl J Med. 2020;383(6):517–25.
Ivermectin for preventing and treating COVID-19. [Cited 28 Jul 2022]. Available from: https://www.cochrane.org/CD015017/INFECTN_ivermectin-preventing-and-treating-covid-19.
Hoertel N, Sánchez-Rico M, Vernet R, Beeker N, Jannot AS, Neuraz A, et al. Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. Mol Psychiatry. 2021;4:1–14.
Hoertel N, Sánchez-Rico M, Kornhuber J, Gulbins E, Reiersen AM, Lenze EJ, et al. Antidepressant use and its association with 28-day mortality in inpatients with SARS-CoV-2: support for the FIASMA model against COVID-19. J Clin Med. 2022;11(19):5882.
Fritz BA, Hoerte N, Lenze EJ, FJalali, Reiersen AM. Association between antidepressant use and ED or hospital visits in outpatients with SARS-CoV-2. Transl Psychiatry. 2022;12(1):1–9.
Lenze E. Fluvoxamine for early treatment of COVID-19: a fully-remote, randomized placebo controlled trial. clinicaltrials.gov; 2021 May [Cited 7 Jun 2021]. Report No.: NCT04668950. Available from: https://clinicaltrials.gov/ct2/show/NCT04668950.
Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020;324(22):2292.
Seftel D, Boulware DR. Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open Forum Infect Dis. 2021 [cited 2021 Jun 9];8(2). https://doi.org/10.1093/ofid/ofab050.
Reis G, Moreira-Silva EA dos S, Silva DCM, Thabane L, Milagres AC, Ferreira TS, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2021 [cited 2021 Nov 8];0(0). Available from: https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00448-4/fulltext.
Oskotsky T, Marić I, Tang A, Oskotsky B, Wong RJ, Aghaeepour N, et al. Mortality risk among patients with COVID-19 prescribed selective serotonin reuptake inhibitor antidepressants. JAMA Netw Open. 2021;4(11):e2133090.
Bramante CT, Huling JD, Tignanelli CJ, Buse JB, Liebovitz DM, Nicklas JM, et al. Randomized trial of metformin, ivermectin, and fluvoxamine for COVID-19. N Engl J Med. 2022;387(7):599–610.
McCarthy MW, Naggie S, Boulware DR, Lindsell CJ, Stewart TG, Felker GM, et al. Effect of fluvoxamine vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2023;329(4):296–305.
Fred SM, Kuivanen S, Ugurlu H, Casarotto PC, Levanov L, Saksela K, et al. Antidepressant and antipsychotic drugs reduce viral infection by SARS-CoV-2 and fluoxetine shows antiviral activity against the novel variants in vitro. Front Pharmacol. 2022 [cited 2023 Feb 16];12. Available from: https://www.frontiersin.org/articles/10.3389/fphar.2021.755600.
Glebov OO. Low-dose fluvoxamine modulates endocytic trafficking of SARS-CoV-2 spike protein: a potential mechanism for anti-COVID-19 protection by antidepressants. Front Pharmacol. 2021;12:3466.
Zimniak M, Kirschner L, Hilpert H, Geiger N, Danov O, Oberwinkler H, et al. The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue. Sci Rep. 2021;11(1):5890.
Carpinteiro A, Edwards MJ, Hoffmann M, Kochs G, Gripp B, Weigang S, et al. Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells. Cell Rep Med. 2020;1(8):100142.
Perera G, Broadbent M, Callard F, Chang CK, Downs J, Dutta R, et al. Cohort profile of the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLaM BRC) Case Register: current status and recent enhancement of an Electronic Mental Health Record-derived data resource. BMJ Open. 2016;6(3):e008721.
Davis KAS, Broadbent M, Bishara D, Mueller C, Stewart R. Can medication mentions in CRIS be used for researching medication use in older people with dementia? Comparing the natural language processing app for medicines to GP prescribing. medRxiv; 2023 [cited 2023 Feb 21]. p. 2023.01.27.23285104. Available from: https://www.medrxiv.org/content/10.1101/2023.01.27.23285104v1.
ICD-10 Version:2019. [cited 2022 Aug 15]. Available from: https://icd.who.int/browse10/2019/en#/.
HoNOS. Healthy London Partnership. [cited 2022 Aug 11]. Available from: https://www.healthylondon.org/resource/outcome-measures/honos/.
Stata | FAQ: Citing Stata software, documentation, and FAQs. [cited 2022 Aug 15]. Available from: https://www.stata.com/support/faqs/resources/citing-software-documentation-faqs/.
Tran BX, Ha GH, Vu GT, Nguyen LH, Latkin CA, Nathan K, et al. Indices of change, expectations, and popularity of biological treatments for major depressive disorder between 1988 and 2017: a scientometric analysis. Int J Environ Res Public Health. 2019;16(13):2255.
Coronavirus disease (COVID-19): Herd immunity, lockdowns and COVID-19. [cited 2022 Aug 12]. Available from: https://www.who.int/news-room/questions-and-answers/item/herd-immunity-lockdowns-and-covid-19.
Ma Y, Li S, Yang H, Zhang Y, Li H, Xu F, et al. Effect of psychotropics on the risk of COVID-19 in middle-aged and older adults. Eur Neuropsychopharmacol. 2023;66:67–77.
Nemani K, Williams SZ, Olfson M, Leckman-Westin E, Finnerty M, Kammer J, et al. Association between the use of psychotropic medications and the risk of COVID-19 infection among long-term inpatients with serious mental illness in a New York state–wide psychiatric hospital system. JAMA Netw Open. 2022;5(5):e2210743.
Machado M, Iskedjian M, Ruiz I, Einarson TR. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr Med Res Opin. 2006;22(9):1825–37.
Tummino TA, Rezelj VV, Fischer B, Fischer A, O’Meara MJ, Monel B, et al. Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2. Science. 2021;373(6554):541–7.
Sukhatme VP, Reiersen AM, Vayttaden SJ, Sukhatme VV. Fluvoxamine: a review of its mechanism of action and its role in COVID-19. Front Pharmacol. 2021 [cited 2023 Feb 16];12. Available from: https://www.frontiersin.org/articles/10.3389/fphar.2021.652688.
Lu Y, Ho CS, Liu X, Chua AN, Wang W, McIntyre RS, et al. Chronic administration of fluoxetine and pro-inflammatory cytokine change in a rat model of depression. PLoS One. 2017;12(10):e0186700.
Hashimoto K. Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor. Eur Arch Psychiatry Clin Neurosci. 2021;5:1–10.
Kapoor R, Peyear TA, Koeppe RE, Andersen OS. Antidepressants are modifiers of lipid bilayer properties. J Gen Physiol. 2019;151(3):342–56.
Creese B, Khan Z, Henley W, O’Dwyer S, Corbett A, Silva MVD, et al. Loneliness, physical activity, and mental health during COVID-19: a longitudinal analysis of depression and anxiety in adults over the age of 50 between 2015 and 2020. Int Psychogeriatr. 2021;33(5):505–14.
Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J. 2020 [cited 2022 Aug 12];55(4). Available from: https://erj.ersjournals.com/content/55/4/2000607.
